- For moderate-to-severe ulcerative colitis (UC), this post hoc analysis suggests that more patients achieve remission with infliximab (Remicade; Janssen Biotech) and do so more quickly than with golimumab (Simponi; Janssen Biotech).
Why this matters
- Head-to-head trials comparing treatment options for moderate-to-severe UC are lacking.
- Among the TNF-α antagonists, network meta-analysis has suggested infliximab may work better.
- Post hoc analysis of individual patient data from phase 3 ACT-1, ACT-2, and PURSUIT-SC trials comparing standard-dose infliximab and golimumab, available through Yale Open Database Access (YODA; n=1793).
- Authors adjusted extensively for patient-level covariates.
- Outcome: patient-reported outcome 2 remission (PRO2, composite of rectal bleeding score of 0 and stool frequency score ≤1 at week 2); clinical remission (Mayo Clinic Score
- Funding: NIH.
- Infliximab vs golimumab:
- PRO2: 35.0% vs 30.0%; aOR, 1.71 (95% CI, 1.15-2.55).
- PRO at week 6: 50.0% vs 38.9%; aOR, 2.03 (1.40-2.94).
- Clinical remission: aOR, 3.01 (1.95-4.70).
- Proof would require head-to-head comparison study.
- Comparison applies only to induction, not maintenance.